List view / Grid view
9 September 2015 | By Victoria White
In vivo administration of Col-Treg in the model of autoimmune uveitis significantly inhibited clinical symptoms, retinal tissue lesions as well as ocular proinflammatory cell infiltration...
18 March 2015 | By Victoria White
TxCell SA has announced that a key patent, covering its lead product Ovasave(R) in IBD, is to be granted in the US on 31 March 2015...
26 February 2015 | By TxCell
TxCell invited to speak at largest US meeting for investors in emerging growth companies...
5 February 2015 | By TxCell
TxCell, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, reports its revenues as of December 31, 2014 and updates on forthcoming milestones...
30 January 2015 | By TxCell
TxCell SA announces its financial calendar for 2015...
29 January 2015 | By TxCell
Milestone payment triggered by first patient enrolment in the phase IIb clinical trial for refractory Crohn’s disease...
27 January 2015 | By TxCell
TxCell SA, a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces the receipt of EUR 1.7 million from Bpifrance...
6 January 2015 | By TxCell
TxCell SA (FR0010127662 – TXCL) announces that the European Commission (EC) has granted orphan drug designation to TxCell's investigational medicinal product Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of autoimmune uveitis...
28 October 2014 | By TxCell
TxCell set for phase I/II proof of principle clinical study in Q2 2015 for its second therapeutic candidate in this rare eye disease...
